A phase II trial of paclitaxel and epirubicin in advanced breast cancer

D. Rischin, J. Smith, M. Millward, C. Lewis, M. Boyer, G. Richardson, G. Toner, H. Gurney, J. McKendrick

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer. performance status 0-2, measurable disease. and a normal left ventricular ejection fraction. who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m-2 followed by a 3-h infusion of paclitaxel 175 mg m-2 repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67% patients received the maximum of six cycles. The response rate was 54% (95% CI 38-69%), 12% CR and 42% PR. Estimated median progression-free survival was 6.9 months (95% CI 5.4-10.0) and estimated median overall survival was 17.9 months (95% CI 14.2-25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥ 20% of baseline value, and in two patients the LVEF decreased to below the lower limit of normal. but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56% cycles, but only 4% of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m-2 and epirubicin 75 mg m-2 is a well tolerated, promising regimen for the treatment of advanced breast cancer. (C) 2000 Cancer Research Campaign.

LanguageEnglish
Pages438-442
Number of pages5
JournalBritish Journal of Cancer
Volume83
Issue number4
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Epirubicin
Paclitaxel
Breast Neoplasms
Stroke Volume
Febrile Neutropenia
Adjuvant Chemotherapy
Neutropenia
Doxorubicin
Disease-Free Survival
Heart Failure
Safety
Survival

Keywords

  • Anthracyclines
  • Breast cancer
  • Phase II
  • Taxanes

Cite this

Rischin, D., Smith, J., Millward, M., Lewis, C., Boyer, M., Richardson, G., ... McKendrick, J. (2000). A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer, 83(4), 438-442.
Rischin, D. ; Smith, J. ; Millward, M. ; Lewis, C. ; Boyer, M. ; Richardson, G. ; Toner, G. ; Gurney, H. ; McKendrick, J. / A phase II trial of paclitaxel and epirubicin in advanced breast cancer. In: British Journal of Cancer. 2000 ; Vol. 83, No. 4. pp. 438-442.
@article{109c231c8304420a92bf46941fb33e93,
title = "A phase II trial of paclitaxel and epirubicin in advanced breast cancer",
abstract = "Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer. performance status 0-2, measurable disease. and a normal left ventricular ejection fraction. who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m-2 followed by a 3-h infusion of paclitaxel 175 mg m-2 repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67{\%} patients received the maximum of six cycles. The response rate was 54{\%} (95{\%} CI 38-69{\%}), 12{\%} CR and 42{\%} PR. Estimated median progression-free survival was 6.9 months (95{\%} CI 5.4-10.0) and estimated median overall survival was 17.9 months (95{\%} CI 14.2-25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥ 20{\%} of baseline value, and in two patients the LVEF decreased to below the lower limit of normal. but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56{\%} cycles, but only 4{\%} of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m-2 and epirubicin 75 mg m-2 is a well tolerated, promising regimen for the treatment of advanced breast cancer. (C) 2000 Cancer Research Campaign.",
keywords = "Anthracyclines, Breast cancer, Phase II, Taxanes",
author = "D. Rischin and J. Smith and M. Millward and C. Lewis and M. Boyer and G. Richardson and G. Toner and H. Gurney and J. McKendrick",
year = "2000",
language = "English",
volume = "83",
pages = "438--442",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Springer, Springer Nature",
number = "4",

}

Rischin, D, Smith, J, Millward, M, Lewis, C, Boyer, M, Richardson, G, Toner, G, Gurney, H & McKendrick, J 2000, 'A phase II trial of paclitaxel and epirubicin in advanced breast cancer', British Journal of Cancer, vol. 83, no. 4, pp. 438-442.

A phase II trial of paclitaxel and epirubicin in advanced breast cancer. / Rischin, D.; Smith, J.; Millward, M.; Lewis, C.; Boyer, M.; Richardson, G.; Toner, G.; Gurney, H.; McKendrick, J.

In: British Journal of Cancer, Vol. 83, No. 4, 2000, p. 438-442.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A phase II trial of paclitaxel and epirubicin in advanced breast cancer

AU - Rischin, D.

AU - Smith, J.

AU - Millward, M.

AU - Lewis, C.

AU - Boyer, M.

AU - Richardson, G.

AU - Toner, G.

AU - Gurney, H.

AU - McKendrick, J.

PY - 2000

Y1 - 2000

N2 - Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer. performance status 0-2, measurable disease. and a normal left ventricular ejection fraction. who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m-2 followed by a 3-h infusion of paclitaxel 175 mg m-2 repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67% patients received the maximum of six cycles. The response rate was 54% (95% CI 38-69%), 12% CR and 42% PR. Estimated median progression-free survival was 6.9 months (95% CI 5.4-10.0) and estimated median overall survival was 17.9 months (95% CI 14.2-25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥ 20% of baseline value, and in two patients the LVEF decreased to below the lower limit of normal. but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56% cycles, but only 4% of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m-2 and epirubicin 75 mg m-2 is a well tolerated, promising regimen for the treatment of advanced breast cancer. (C) 2000 Cancer Research Campaign.

AB - Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer. performance status 0-2, measurable disease. and a normal left ventricular ejection fraction. who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m-2 followed by a 3-h infusion of paclitaxel 175 mg m-2 repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67% patients received the maximum of six cycles. The response rate was 54% (95% CI 38-69%), 12% CR and 42% PR. Estimated median progression-free survival was 6.9 months (95% CI 5.4-10.0) and estimated median overall survival was 17.9 months (95% CI 14.2-25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥ 20% of baseline value, and in two patients the LVEF decreased to below the lower limit of normal. but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56% cycles, but only 4% of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m-2 and epirubicin 75 mg m-2 is a well tolerated, promising regimen for the treatment of advanced breast cancer. (C) 2000 Cancer Research Campaign.

KW - Anthracyclines

KW - Breast cancer

KW - Phase II

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=0033915789&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 438

EP - 442

JO - British Journal of Cancer

T2 - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -

Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G et al. A phase II trial of paclitaxel and epirubicin in advanced breast cancer. British Journal of Cancer. 2000;83(4):438-442.